FelkerGM, O'ConnorCM, BraunwaldE: Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil?. Circ Heart Fail, 2009; 2:56–62.
2.
McMurrayJJV, AdamopoulosS, AnkerSD, et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail, 2012; 14:803–869.
3.
HuntSA, BakerDW, ChinMH, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. Circulation, 2001; 104:2996–3007.
4.
FarlessLB, SteilN, WilliamsBR, BaileyFA: Intermittent subcutaneous furosemide: Parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic. Am J Hosp Palliat Med, 2013; 30:791–792.
5.
GadoudA, JenkinsSM, HoggKJ: Palliative care for people with heart failure: Summary of current evidence and future direction. Palliat Med, 2018; 27:822–828.
6.
LumHD, HorneyC, KoetsD, KutnerJS, MatlockDD: Availability of heart failure medications in hospice care. Am J Hosp Palliat Med, 2016; 33:924–928.
VermaAA: Diuretic effects of subcutaneous furosemide in human volunteers: A randomized pilot study. Pharmacotherapy, 2004; 38:544–549.
10.
ZachariasH, et al.: Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?. Palliat Med, 2011; 25:658–663.
11.
BeattieJM, JohnsonMJ: Subcutaneous furosemide in advanced heart failure: Has clinical practice run ahead of the evidence base?. BMJ Support Palliat Care, 2012; 2:5–6.
12.
SchwartzGH, et al.: Ototoxicity induced by furosemide. N Engl J Med, 1970; 282:1413–1414.
13.
ChengHWB, ShamMK, et al.: Combination therapy with low-dose metolazone and furosemide: A “needleless” approach in managing refractory fluid in elderly renal failure patients under palliative care. Int Urol Nephrol, 2014; 46:1809–1813.
14.
LeonardCE, et al.: Empiric potassium supplementation and increased survival in users of loop diuretics. PLoS One, 2014; 9:e102279.
